Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06258304 · ClinicalTrials.gov registry record · Phase 1
A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
A Phase 1 study of Advanced or Metastatic Solid Tumor Malignancies, sponsored by GigaGen.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT06258304 is a Phase 1 study of Advanced or Metastatic Solid Tumor Malignancies that is actively recruiting participants, run by GigaGen. The registered enrollment target is 60 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06258304, a Phase 1 study of Advanced or Metastatic Solid Tumor Malignancies, is actively recruiting participants, sponsored by GigaGen.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the safety and tolerability of GIGA-564 and identify the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) level(s) of GIGA-564 in participants with metastatic or locally advanced solid tumor malignancies.
Conditions Studied
Interventions
- DRUG GIGA-564
Study Locations (1)
Maryland
- National Cancer Institute - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-05-08 |
| Est. Completion | 2027-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06258304
The ClinicalTrials.gov registry entry for NCT06258304 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GigaGen, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced or Metastatic Solid Tumor Malignancies appearing as the primary indexed condition, and to 1 intervention - of which GIGA-564 is the first listed.
NCT06258304 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT06258304 about?
NCT06258304 is a clinical study titled "A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies". The purpose of this study is to assess the safety and tolerability of GIGA-564 and identify the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) level(s) of GIGA-564 in participants with metastatic or locally advanced solid tumor malignancies.
What is the current status of trial NCT06258304?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2024-05-08. Estimated completion is 2027-11.
What conditions does trial NCT06258304 study?
This clinical trial studies the following conditions: Advanced or Metastatic Solid Tumor Malignancies.
What interventions are being tested in trial NCT06258304?
The interventions under investigation include: GIGA-564 (DRUG).
Who is sponsoring clinical trial NCT06258304?
This trial is sponsored by GigaGen, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06258304 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced or Metastatic Solid Tumor Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.